With a market capitalization of $18.4 billion, Insulet Corporation (PODD) is a leading developer of innovative insulin delivery systems for patients with insulin-dependent diabetes. The company's flagship product, Omnipod System, offers a tubeless wearable insulin pump with wireless capabilities, providing a modest and easy-to-use solution for continuous insulin delivery.
Companies worth more than $10 billion are generally classified as “large” stocks, and insulets meet this standard perfectly. Headquartered in Acton, Massachusetts, Insulet is partnering with pharmaceutical and biotechnology companies to expand the application of other subcutaneous drugs.
Active Investors: Free newsletter behind the hottest stock headlines to uncover new trade ideas
Insulin infusion system manufacturers fell 10.7% from their 52-week high of $289.46. Over the past three months, PODD stocks have declined slightly, falling below the 4.7% increase in Healthcare Select SPDR Fund (XLV) over the same period.
In the long term, PODD is slightly reduced on a YTD basis, lagging behind the 4.7% gain of XLV. Nevertheless, Insulet's shares have risen 53.8% over the past 52 weeks, with 1.7% of XLV falling in the same time frame.
PODD has been trading more than 50 days and above the 200-day moving average since last year. However, inventory is below the 50-day moving average from late February.
Insulett fell 1.9% the following day despite reporting a quarter adjusted EPS of $1.15, which was better than expected and revenue of $597.5 million on February 20. Operating profit margin fell by 258 basis points from the previous year due to a 22.6% increase in sales, general and administrative expenses and a 44.3% increase in research and development costs. Additionally, Insulet predicted a sharp decline of 45% to 55% in drug delivery revenue in 2025, obscuring strong Omnipod revenue growth forecasts of 17-21%.
However, Podd is better than its competitor Abbott Laboratories (ABT), which has experienced a 17.5% increase in the last 52 weeks. However, ABT rose 16.4% on a YTD basis, surpassing PODD.
The strong price action of Insulet over the past year has made analysts bullish about the outlook. The stock has a “strong buy” consensus rating from 22 analysts covering the stock, and at the time of writing it is below the average price target of 317.90.
On the date of publication, Sohini Mondal had no position (directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. For more information, see BarChart's disclosure policy.
More news from the bar chart
The views and opinions expressed herein are the views and opinions of the authors and are not necessarily Nasdaq, Inc. It does not reflect the opinions of
